A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy
Read time: 1 mins
Last updated:26th Apr 2011
Phase I: The primary objective is to find the safe and potentially efficacious dose of eltrombopag to achieve a durable increase in platelet count. Phase II: The primary objective of phase II is to confirm the effect of the selected dose from Phase I in correcting thrombocytopenia to enable patients to receive alkylating agents and/or purine analogue-based therapy.
|Study start date||2011-04-26|